Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Rationale: Understanding the mechanisms of enzalutamide as an androgen receptor inhibitor in
early prostate cancer could lead to improved patient selection for treatment.
Objective: To study the effects of enzalutamide on surgical margin status and AR / DNA
interaction and gene expression.
Intervention : Men with localized prostate cancer will undergo an additional set of targeted
tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The
prostatectomy specimen will be additionally sampled, ex vivo.